Market Place
Sourcing Support
All News #Library
Biotech
Bolt Bio Reports 2025 Financials And Business Update
12 Mar 2026 //
GLOBENEWSWIRE
Bolt Biotherapeutics To Participate In Upcoming March Conferences
24 Feb 2026 //
GLOBENEWSWIRE
Bolt Bio Updates BDC-4182, Extends Cash Runway To 2027
01 Oct 2025 //
GLOBENEWSWIRE
Bolt Bio to Host KOL Conference on BDC-3042 Phase 1 Result
08 May 2025 //
GLOBENEWSWIRE
Bolt Biotherapeutics Presents Phase 1 Study Results at AACR 2025
25 Apr 2025 //
GLOBENEWSWIRE
Bolt Biotherapeutics Reports Q4 and Full-Year 2024 Results
24 Mar 2025 //
GLOBENEWSWIRE
Bolt Biotherapeutics Updates on BDC-4182 & BDC-1001 Data at SITC
07 Nov 2024 //
GLOBENEWSWIRE
Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Financial Results
21 Mar 2024 //
GLOBENEWSWIRE
Bolt Enrolls First Patient in Phase 2 Clinical Study Evaluating BDC-1001
05 Dec 2023 //
GLOBENEWSWIRE
Bolt to Present Data at the Society for Immunotherapy of Cancer™s 2023 Meeting
18 Oct 2023 //
GLOBENEWSWIRE
Bolt Announces First Patient Dosed in Phase 1/2 Study of BDC-3042 in Patients
17 Oct 2023 //
GLOBENEWSWIRE
Bolt to Present New Clinical Data from Completed Phase 1/2 of BDC-1001
16 Oct 2023 //
GLOBENEWSWIRE
Bolt Highlights Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001
25 May 2023 //
GLOBENEWSWIRE
Bolt to Present Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001
26 Apr 2023 //
GLOBENEWSWIRE
Positive topline data for Bolt’s BDC-1001 in HER2 solid tumours
30 Mar 2023 //
CLINICAL TRIALS ARENA
Bolt Announces Positive Data from BDC-1001 PI Trial in HER2-Expressing Tumors
29 Mar 2023 //
GLOBENEWSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.